Saturday 17 October 2026
Export CTMX’s income statement to Excel — free account
CytomX Therapeutics, Inc.
CTMX Healthcare Biotechnology
CytomX Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $76.2 million, down 44.8% from fiscal 2024. In the quarter to June 2026, revenue fell 92.4%, EPS fell 7,400.0% and free cash flow fell 14.5%, each against the same quarter a year earlier.
2.27
0.14
−5.81%
Follow CTMX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (39.18%) | (36.03%) | (41.34%) | 66.76% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
3 | 2 | 2 | 5 | |
| (29.72%) | (27.15%) | (14.97%) | 18.85% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(24.72%) | (19.41%) | (20.66%) | 25.49% | |
Average Days of Receivables |
747.75 | 6.63 | 9.64 | 5.23 | |
Free Cash Flow per Share |
(0.38) | (0.45) | (0.55) | (0.44) | |
Free Cash Flow |
(82.41) | (80.09) | (75.81) | (72.35) | |
Capital Expenditures |
— | — | (0.22) | (0.10) | |
| Other line items | |||||
Cash ROIC |
(13.01%) | (12.01%) | (32.11%) | (28.82%) | |
Accounts Receivable Turnover |
0.93 | 27.32 | 29.79 | 45.63 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.01 | (0.01) | |
Research and Development Expense of Revenue |
400.91% | 194.41% | 90.19% | 54.81% | |
Selling, General and Administrative Expense of Revenue |
175.28% | 87.50% | 39.16% | 24.73% | |
Share Based Compensation of Revenue |
55.44% | 25.32% | 8.27% | 5.90% | |
Operating CF/Net income |
1.00 | 1.29 | 3.71 | (2.58) | |
Depreciation/Fixed assets |
(2.38) | (1.13) | (0.64) | (0.58) | |
Capex/Depreciation |
0.00 | 0.00 | 0.27 | 0.10 | |
Revenue per Share |
0.08 | 0.20 | 0.55 | 0.69 | |
Operating CF per Share |
(0.38) | (0.45) | (0.55) | (0.44) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates